We are delighted to announce two special sessions below to be included in the programme for the meeting in Harrogate next month. These will address important topics in psychopharmacology, drawing on BAP expertise, and should be of interest to much of the membership. However they should have particular value to clinical staff including psychiatrists and pharmacists wishing to keep up-to-date with advances and current concerns in the pharmacotherapy of major psychiatric disorders.

Current guidelines for the treatment of schizophrenia and bipolar disorder

To be held at the Old Swan Hotel, Harrogate, on Sunday 25 July 2010 at 17:30

17:30  Tea
17:45  Chairman’s Introduction
       Professor Nicol Ferrier
17:50  BAP guidelines for the treatment of schizophrenia
       Professor Thomas Barnes
18:15  Questions and discussion
18.25  Guidelines for the treatment of bipolar disorder – an update
       Professor Guy Goodwin
18.50  Questions and discussion
19:00  Close

This BAP-led session is sponsored by an unrestricted educational grant from MSD (approval pending)

Evidence-based management of common problems during antidepressant treatment

To be held at the Old Swan Hotel, Harrogate, on Monday 26 July 2010 at 18:15

18:15  Tea
18:45  Introduction by Chair Hamish McAllister-Williams
18:55  Management of discontinuation symptoms with antidepressant drugs Peter Haddad
19:20  Management of sexual dysfunction with antidepressant drugs David Baldwin
19:45  Questions and discussion
19:55  Closing comments by Chair

This BAP-led session is sponsored by an unrestricted educational grant from Servier
2010 ELECTION FOR OFFICERS AND COUNCIL - PLEASE USE YOUR VOTE

President-elect
Professor Barbara Sahakian was proposed by Professor Nicol Ferrier and seconded by Professor Gavin Reynolds

There were no further nominations for this post, so Professor Sahakian will be elected unopposed

Meetings Secretary
Professor Jo Neill was proposed by Dr Alan Bateson and seconded by Professor Charles Marsden

There were no further nominations for this post, so Professor Neill will be elected unopposed

Secretary for Clinical External Affairs
Professor Naomi Fineberg was proposed by Professor Trevor Robbins and seconded by Dr David Baldwin

There were no further nominations for this post, so Professor Fineberg will be elected unopposed

Council vacancies
The following nominations have been received and are valid:

<table>
<thead>
<tr>
<th>Nominee</th>
<th>Proposed By</th>
<th>Seconded By</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Stephen Bazire</td>
<td>Professor Gavin Reynolds</td>
<td>Dr Peter Haddad</td>
</tr>
<tr>
<td>Dr Marcus Munafo</td>
<td>Professor David Nutt</td>
<td>Dr Catherine Harmer</td>
</tr>
<tr>
<td>Dr Digby Quested</td>
<td>Professor Philip Cowen</td>
<td>Dr Catherine Harmer</td>
</tr>
<tr>
<td>Dr Elizabeth Tunbridge</td>
<td>Professor Paul Harrison</td>
<td>Professor Jo Neill</td>
</tr>
</tbody>
</table>

Biographies and statements of intent for the Council nominees are available on the website, together with voting facilities. Voting will be conducted online only. All Full, Honorary and Retired Full Members are entitled to vote. Deadline for receipt of votes: Monday, 19 July. The results will be announced at the Annual General Meeting (26 July in Harrogate).

ON THE BAP WEBSITE (www.bap.org.uk):

The following documents are available for Members:

- Minutes of the 2009 Annual General Meeting
- 2009 Audited accounts
- Biographies and Statements of Intent for the 2010 Council nominees
- Full information for the 2010 Summer Meeting

BAP PSYCHOOPHARMACOLOGY AWARDS 2010

We are delighted to announce that two Awards will be presented this year:

Valeria Mondelli
Institute of Psychiatry, London

Jared Young
University of California, San Diego

Valeria and Jared will each make an oral presentation on 26 July at the summer meeting in Harrogate. They will receive their Awards at the conference dinner on 27 July.
ROBERT KERWIN BURSARIES

Bursaries have this year been awarded to:

**Sally Adams (Bristol)**
To attend the 72nd Annual Meeting of the College on Problems of Drug Dependence

**Livia Carvalho (London)**
To attend the American College of Neuropsychopharmacology Annual Meeting

Professor Robert Kerwin was instrumental in advising, supporting and acting as mentor for numerous people early in their careers in psychopharmacology. To commemorate this, the Council of the British Association for Psychopharmacology introduced annual bursaries in 2008, to be awarded in his name.

The bursaries are available to individuals who are current Members of BAP and have held their membership for a minimum of 6 months. Applicants will be studying for a higher degree (PhD, MD) or will have been awarded such a degree in the last 3 years. Each bursary covers travel expenses and the registration fee for an international conference, together with subsistence. The conference could be held in the UK, but should be international, and will take place between July of the current year and June of the next year.

Bursary recipients are expected to attend the BAP Summer Meeting and also write an article for the BAP Newsletter. Full details are on the website.

---

**2010 ANNUAL GENERAL MEETING**

This will be held in the Queen's Suite at Harrogate International Centre on Monday, 26 July, 16:45-18:15. Items for discussion should be emailed to Susan Chandler by Monday 19 July.

**ON THE BAP WEBSITE:**
The following documents are available for Members:

*Minutes of the 2009 Annual General Meeting*
*2009 Audited accounts*
*Biographies and Statements of Intent for the 2010 Council nominees*
*Full information for the 2010 Summer Meeting*

---

**CONGRATULATIONS**

Congratulations to **Professor Barbara Sahakian** (President-elect of BAP from July), who has been invited to present the plenary talk at the “Celebration of Women in Neuroscience” lunch on Tuesday, November 16 at the Society for Neuroscience meeting (13-17 November, San Diego; http://www.sfn)

Barbara has also been awarded the 2010 International College of Geriatric Psychoneuropharmacology (ICGP) Senior Investigator Award, based on her outstanding contribution over many years to translational cognitive psychopharmacology and the study of emotional and behavioural dysfunction.
SUNDAY 25 JULY

09:00  BAP Council meeting
11:00  Registration and Exhibition set-up at Harrogate International Centre
13:30-17:00 Preclinical Certificate Module at HIC
17:30-19:00 Special Session at The Old Swan “Guidelines for the treatment of schizophrenia and bipolar illness”
19:30  Welcome Reception at The Old Swan

MONDAY 26 JULY

9-11.30am  3 symposia in parallel at HIC:
Symposium 1:  Advances in understanding cannabinoids: implications for psychosis, dependence and cognition
Symposium 2:  The mood-psychosis spectrum: implications for psychopharmacology.
Symposium 3:  Pharmacological MR: fulfilling its promise?

11:30–12:15  Poster Preview
12:15-3:15  Lunch
13:15-14:45 Poster Session 1 in Hall D
Including the following groups: Schizophrenia 1 / Affective Disorders 1 / Sleep / Substances of Abuse 1 / Imaging / Neuropharmacology

15:00-16:00  Guest Lecture presented by Professor Trevor Robbins
16:00-16:30  BAP Psychopharmacology Award Winners: Oral Presentations
Dr Jared Young and Dr Valeria Mondelli
16:45-18:15  BAP Annual General Meeting

18:15  Two events at The Old Swan Hotel:
BAP Special Session “Evidence-based management of common problems during antidepressant treatment”
Satellite symposium hosted by Janssen (title pending)
TUESDAY 27 JULY

09:00-11:30 3 symposia in parallel at HIC
  Symposium 4: Sex differences in Psychopharmacology.
  Symposium 5: Severe and chronic treatment resistant depression - emerging neurobiology
  Symposium 6: Dopamine: what is it doing in addiction?

11:45-12:45 Post-doc Symposium “Stress and Psychiatry”

12:45-14:00 Editorial Board Meeting

12:45-14:00 Lunch and Poster Preview

14:00-15:30 Poster Session 2 in Hall D
  Including the following groups: Schizophrenia 2 / Affective Disorders 2 / Psychomotor Stimulants / Substances of Abuse 2 / Cognition / Dementia / Feeding and Eating Disorders / Anxiety / Undergraduate Abstracts

15:30-16:30 Short Oral Sessions
  SO 1: Emerging role for nicotine acetylcholine receptors as a novel drug target
  SO 2: New viewpoints on substance use
  SO 3: Translational models of impulsivity

16:45-17:45 Meeting of the RCPsych Psychopharmacology Special Interest Group

19:00 Reception at The Old Swan for those attending the Conference Dinner

19:45 Conference Dinner / Prize giving / speeches / disco

WEDNESDAY 28 JULY

09:30-12:00 3 symposia in parallel at HIC:
  Symposium 7: Advances in modelling schizophrenia in the rodent
  Symposium 8: Are treatment trials becoming more relevant for the clinical scenario?
  Symposium 9: Lithium: multiple cellular and clinical effects

Meeting ends at 12:00 Wednesday 28 July

2010 SUMMER MEETING VENUE

Initial programmes for the forthcoming Summer Meeting cited The Majestic Hotel in Harrogate as one of the venues to be used for our event. However the Majestic suffered a fire earlier this year and is therefore closed until further notice. As a result, we have re-located a number of our events to The Old Swan Hotel, Swan Road, Harrogate HG1 2SR (http://www.classiclodges.co.uk/The_Old_Swan_Hotel_Harrogate/)
2010 BAP LIFETIME ACHIEVEMENT AWARD

A. Richard Green

Richard Green will receive the BAP Life time Achievement award at the 2010 summer meeting in Harrogate. It gives me great pleasure to write a few words about his long and fruitful career in research into the action of drugs on the brain during the course of which he has helped so many young scientists achieve their ambitions and given a lot pleasure to all of us who have had an opportunity to collaborate with Richard.

Mention of serotonin and depression immediately brings to mind an association with Richard Green. Richard’s love affair with serotonin dates back to his PhD work in Gerald Curzon’s laboratory at The Institute of Neurology in London (1966-1970) and extends through a very productive dual act with another BAP Life time Achievement winner, David Graehme-Smith, at Oxford between 1973-1985. Between 1970 and 1973 Richard was an International visiting fellow at NIMH in Washington working in Erminio Costa’s laboratory. In 1986 Richard left Oxford to take up the exciting challenge of Director of the newly created Astra Neuroscience Research Unit in London based within The Institute of Neurology. This was not only exciting because it was a new venture but it also involved a change in research direction away from serotonin and mental disorders to neurodegeneration and protection. Richard however quickly found a way of incorporating serotonin into the new research profile through the establishment of another long and productive collaboration with Isobel Colado, from Complutense University in Madrid, looking at the neurotoxicity of MDMA (Ecstasy). Richard later became Director, Global Discovery CNS and Pain at AstraZeneca and a Special Professor of Neuropharmacology at The University of Nottingham and while he has now retired from the former he still very much retains a role in the latter.

In the area of serotonin the contributions made by Richard’s work have had profound effects on what has been achieved experimentally and our understanding of the role of this neurotransmitter. In the former case the development of a rapid assay for 5HT and 5HIAA (Curzon G and Green AR (1970) Br.J.Pharmacol. 39: 653-655) in brain regions opened up the possibility of investigating regional differences in response to both pharmacological and physiological events. The method dominated serotonin research in the 1970s even if it did expose a generation of neuropharmacologists to the potentially lethal combination of boiling -pthaldehyde with HCl — we didn’t mind as long as we got the results! The method was gradually replaced by HPLC with electrochemical detection in the late 1970s. The studies with David Graehme-Smith using the ‘serotonin syndrome’ as a model of serotonin function altered the way we thought about serotonin regulation (Green AR and Graehme-Smith DG (1976) Nature 260: 487-491) leading to an interest in the measurement of release rather than metabolism or turnover and onto the identification of the receptors controlling release.

A quick scan of Richard’s published papers clearly shows he is not just serotonin. With a series of collaborators at Oxford, including David Nutt, Phil Cowan and David Heal, Richard started to unravel the antidepressant mechanisms of ECT. From an early stage Richard was involved in studies on the central actions of thyrotrophin releasing hormone (TRH) and its interactions with dopamine and serotonin; this is an area that we collaborated and have published together (Lighthoon C. et al (1984) Neuropharmacology 23: 963-966) on this occasion on the effects of ECT on brain region TRH levels. Since 1986 the focus of Richard’s work moved to the mechanisms involved in the action of putative neuroprotective drugs and I think it an excellent measure of his abilities that Richard so skilfully transferred skills developed in the area of drugs and mental disease to the emerging area of neuroprotection while also taking on new neurotransmitters (GABA and glutamate), neural mechanisms and experimental approaches.

The commitment to pharmacology as a subject by Richard is demonstrated by the energy he gave to The British Pharmacological Society as Meetings Secretary (1986-88) and then General Secretary (1989-91) and in his role as Vice-President (1992-4), President (1994-6) and then Secretary (1997 to 2004) of The Serotonin Club. Both organisations flourished under his watchful eye for detail but an ability to engage all the membership. Richard too has made a very full contribution to the activities of the BAP since its very early days.

The journal Neuropharmacology was a long term beneficiary of Richard’s ability to make decisions plus a great care for detail in his role as first an advisory editor and later an executive editor of the journal – an association that began in 1979 and ran until his retirement in 2006; that is 30 years hard labour. Richard has also given time and expertise to many other important journals including Journal of Psychopharmacology.

I have known Richard almost throughout our two careers; we both graduated from London in 1966 and obtained our PhD’s in 1969. We both had the intellectual excitement of working with Gerald Curzon as I was a postdoc with Gerald from 1972-1977. We both first published in Neuropharmacology at about the same time (Richard in 1974 and me in 1973) and have collaborated on research and in the organisation of scientific meetings. In retirement at Nottingham we have continue to work together on those most important aspects of science – research and PhD training. Richard has unlimited enthusiasm for almost everything with a rich and varied life outside his work environment, just ask him about his canal boat, but he has a special enthusiasm for science and the people involved combined with a great ability to transfer this enthusiasm to others. I am delighted that the BAP has recognised Richard’s special contribution to psychopharmacology.

Charles A Marsden
School of Biomedical Sciences
University of Nottingham Medical School
BAP FORTHCOMING EVENTS

JULY 2010
25 – 28 Summer Meeting in Harrogate
25 Preclinical Certificate Module 5: Functional And Advanced Techniques – The development of pharmacological agents (Optional Module)
Harrogate International Centre

SEPTEMBER 2010
23 – 24 Clinical Certificate Module: Drug Treatments in Affective Disorders (Core Module)
Life Conferences and Banqueting
Newcastle Upon Tyne

OCTOBER 2010
7- 8 Clinical Certificate Module: Drug Treatments in Old Age Psychiatry (Optional Module)
Renaissance Hotel, Manchester

NOVEMBER 2010
4 Preclinical Certificate Module 6: Principles of Psychiatry for Basic Scientists, Bristol
24 BAP Masterclasses: Schizophrenia / Substance Misuse, 76 Portland Place, London
25 BAP Masterclasses: Bipolar / Perinatal / ADHD, 76 Portland Place, London
26 BAP Masterclasses: Depression / Anxiety / Sleep, 76 Portland Place, London

JANUARY 2011
20 – 21 Clinical Certificate Module: Anxiety Disorders (Core Module)
The Bristol Hotel, Bristol

MARCH 2011
Date tbc Clinical Certificate Module: Child and Adolescent Psychopharmacology (Optional Module)
Nottingham

APRIL 2011
20 BAP Masterclasses: Schizophrenia / Substance Misuse, 76 Portland Place, London
21 BAP Masterclasses: Bipolar / Perinatal / ADHD, 76 Portland Place, London
22 BAP Masterclasses: Depression / Anxiety / Sleep, 76 Portland Place, London

MAY 2011
Date tbc Clinical Certificate Module: Schizophrenia (Core Module), Renaissance Hotel
Manchester
BOOK REVIEWS

Buzzed: The Straight Facts about the Most Used and Abused Drugs from alcohol to ecstasy.
Cynthia Kuhn PhD, Scott Swartzwelder PhD and Wilkie Wilson PhD, Duke University Medical Center

This book was written by Professors of Pharmacology and Psychology at Duke University Medical Center. Following discussions with students, they realised that people know very little about commonly used drugs and that those who use drugs are making high risk choices which are generally not fully informed. This led to their recognition of a need for an informative book on this topic.

The book aims to provide clear, detailed and accurate facts in a user friendly way so that people are able to make better decisions about drugs. There are chapters on alcohol, caffeine, ecstasy, hallucinogens, herbal drugs, inhalants, marijuana, nicotine, opiates, sedatives, steroids and stimulants. Its target audience is wide (adolescents, students, parents, doctors, drugs workers, politicians, legislators). The book has no particular agenda and is divided into Part I and Part II. In Part I, drugs are organised by class. It considers each drug individually and gives an account of the facts and risks. Part II includes basic explanations of pharmacodynamics, pharmacokinetics and neurobiology and also has a Chapter on legal issues. The reader is advised to read Part II first to achieve a broad general understanding.

The book achieves its aim since it is scientifically accurate and packed with information. It is written in the US, and it is therefore not surprising that it has a US slant in parts, particularly in the Chapter about Legal Issues. It is easily navigated so that the reader can easily use it for quick reference as well as read it more methodically. In my opinion, the authors have managed to strike the correct balance between readability and technical detail for most people. It has a particularly engaging quiz with answers at the beginning which inspire the reader to read on to find out more. The glossary of drug-related street terms and slang is particularly impressive. I certainly learnt a lot from this book and I think it is an important resource for anyone who wants or needs to know more about the effects of various drugs on the body and behaviour.

Dr Rachel XA Petrie MRCpsych BSc (Hons) PhD
Consultant Psychiatrist (Addictions)
Glenesk Centre, 1-5 Duke St, Dalkeith EH22 1 BG

Principles of CNS drug development from test tube to patient.

Despite the advances that have been made in many areas of therapeutics in recent years, [for example, in the treatment of infectious diseases, cancers, cardiovascular and inflammatory diseases], treatment of diseases of the brain, with a few exceptions, remain notoriously resistant to a major breakthrough. There are many reasons for this, a primary one being our very limited understanding of the pathological basis of most of the major psychiatric and neurological disorders. In the past, serendipity has played a major role in the development of CNS drugs and even today it is an important contribution towards CNS drug discovery. Nevertheless, this unfortunate history should not detract from attempts to try to rationalise the discovery of better drugs for the treatment of CNS disorders. Undoubtedly this has motivated John Kelly to critically assess the various approaches that are used to develop CNS drugs and has resulted in a very “user friendly” text. This reflects its origin that has been based on over a decade as the co-ordinator and organiser of the MSc neuropharmacology course at the National University of Ireland, Galway. The nine chapters that comprise this volume are divided into three main sections. The first section, of three chapters, serves as an introduction for the subsequent chapters on drug development. Thus following the first chapter on the social and economic aspects of CNS diseases, chapter two summarises the possible neuropathological basis of psychiatric and neurological disorders, concepts which are further developed in chapter three on the neurobiology of CNS diseases.

Section two consists of four chapters and covers the pharmacological targets that have been identified for the development of drugs for the treatment of the major psychiatric and neurological disorders [ mood disorders, psychotic disorders, anxiety disorders, epilepsy and the dementias]. This is followed by a discussion of pre-marketing efficiency evaluation which usefully summarises such issues as target and lead identification, and animal models of CNS diseases and their limitations. The importance of the pharmacokinetic aspects of drug development, and safety considerations, conclude this section. The two final chapters critically assess many of the aspects that were discussed in the previous chapters. Thus chapter eight summarises the important aspects of preclinical and clinical safety evaluation while the final chapter gives a valuable account of novel drug targets in development and what may be expected from such developments in the near future.

John Kelly is to be congratulated in producing a textbook that is not only interestingly written, a pleasure to read and up-to-date [many of the key references were published in 2008] but also for producing a text that contains some exciting and original ideas about CNS drug development. Hopefully it will be read not only by pharmacology undergraduates and postgraduates but also by researchers in the pharmaceutical industry.

Brian E. Leonard, Emeritus Professor of Pharmacology, National University of Ireland, Galway